NeoGenomics, Inc. (NASDAQ:NEO) is reporting second quarter earnings results on Tuesday 28th July 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.1 per share.
For the full year, analysts predict revenues of $ 426.79 million, while looking forward to loss of $ 0.04 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 464.00 million ~ $ 474.00 million
Click Here For More Historical Outlooks Of NeoGenomics, Inc.
Previous Quarter Performance
NeoGenomics, Inc. recorded loss for the first quarter of $ 0.02 per share, from the revenue of $ 106.03 million. The quarterly revenues escalated 17.02 percent compared with the same quarter last year. According to street consensus, NEO was expected to report 1Q20 income of $ 0.02 per share from revenue of $ 104.42 million. The bottom line results missed street analysts by $ 0.04 or 200 percent, at the same time, top line results outshined analysts by $ 1.61 million or 1.54 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of NeoGenomics, Inc.
Stock Performance
According to the previous trading day, closing price of NEO was $ 36.82, representing a 98.81 % increase from the 52 week low of $ 18.52 and a 2.33 % decrease over the 52 week high of $ 37.70.
The company has a market capital of $ 4.04 billion and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”NEO” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 25th June 2020, initiated by Bank of America at Buy rating, with $ 34.00 target price.
Conference Call
NeoGenomics, Inc. will be hosting a conference call at 8:30 AM eastern time on 28th July 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.neogenomics.com
NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The companys laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
